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MC may be efficiently induced in non-malignant genetic disorders, such as marrow failure syndromes and hemoglobinopathies, and this may be enough to reverse the clinical consequences of inborn errors. MC in leukemia patients is a strong indicator of relapse, especially when it is observed after myeloablative conditioning and when MC reveals an increasing number of recipient cells over time. 2 However, long-term MC without relapse has also been described in leukemia patients treated with myeloablative conditioning. [3] [4] [5] Schaap et al. 3 identified 19 leukemia patients with persisting (42 years) MC among 231 transplanted patients. The number of recipient cells in peripheral blood did not exceed 15% in a group of 10 patients, whereas the other 9 patients had a relatively high percentage of persisting autologous cells for a median of 12 years.
The pattern of long-term MC after BMT in leukemia patients usually reveals the presence of both recipient and donor cells in all, or in a given cellular compartment (myeloid, erythroid, lymphoid), indicating that both residual recipient and engrafted donor hematopoiesis exist and are immunotolerant to each other. 1, [3] [4] [5] In contrast, compartmental or split chimerism indicating that the hematopoietic compartments are wholly derived from either donor or recipient has never been described in leukemia patients. 1 Split chimerism is mainly found in cases of SCID for which no myeloablative therapy has been used. 6 In the absence of myeloablation, there is no engraftment of donor stem cells but only a compartmental engraftment of T-cell progenitors resulting in split chimerism in which myeloid and erythroid cells are of host origin, and all T-cells (and NK cells if host NK cells were defective) are of donor origin. In contrast, myeloablative BMT in SCID patients results in complete myeloid, erythroid and lymphoid donor engraftment.
Here, we report a patient with bcr-abl þ ALL who had persisting lymphoid-restricted split chimerism without relapse. A 44-year-old male (blood group B þ ) underwent an allogeneic BMT in 1996 from a matched unrelated donor (blood group 0 þ ). At transplantation, the ALL was in first CR. Myeloablative conditioning was used, consisting of TBI (total 12 Gy) on days À7 to À5, followed by etoposide (VP-16) 50 mg/kg once daily intravenously on day À4, CY 60 mg/kg once daily intravenously on day À2 and rabbit anti-T-cell serum (ATG Fresenius) 20 mg/kg/day on days À3 to À1. On day 0, the patient received 2.8 Â 10 (Table 1) . At the last control in April 2008, we isolated the peripheral myeloid cells (CD15 þ ), T cells (CD3 þ ) and B cells (CD19 þ ) with a FACS sorter (Moflo, Cytomation, Fort Collins, CO, USA) and subjected these purified sub-populations (498% purity) to chimerism analysis ( Figure 1 ). Myeloid cells were recipient-derived (495%), whereas nearly all B-and T-lymphoid cells (495%) were of donor origin (Table 1 ). Blood group was of recipient type (B þ ). Taken together, the patient exhibits a split chimerism with the myeloid and erythroid cells shown to be of recipient origin and the lymphoid cells of donor origin.
There are many possible theories for the presence of MC without relapse of the original leukemia. One explanation might be that the recipient cells detected originate from the malignant clone and represent residual disease controlled by an active donor-derived immune system. However, in our patient, we would expect these cells to be bcr-abl þ . Persisting MC without relapse as described in this case may be explained by complete eradication of the malignant clone with selective survival of residual normal host hematopoietic stem cells that are tolerated by the transplanted donor immune system. Complete eradication of the malignant clone may have resulted either from the myeloablative conditioning and/or alternatively from alloreactive lymphocytes in the graft directed toward leukemiaassociated antigens. In our particular lymphoblastic leukemia case presenting with lymphoid-restricted donor hematopoiesis, the use of ATG combined with GVLmediated cytotoxicity specific to minor lymphoid antigens might have resulted in reactivity directed toward the malignant and normal lymphoid cells but not toward residual myeloid and erythroid cells, thus creating split hematopoiesis without relapse of the original disease. If this is the case, intervention with infusion of donor lymphocytes may have resulted in cytopenia (anemia and or neutropenia) due to anti-host alloreactivity. There are two points in our case indicating that the donor-specific lymphopoiesis is generated from the engraftment of a true stem cell and not due to colonization of the thymus with a donor T-cell progenitor, as is the case in SCID patients. First, there was no exhaustion of the donor-derived lymphopoiesis over the 10-year period, and second not only T cells but also B lymphocytes were donor derived.
Cases with split chimerism give some insights into the development of the human hematopoietic system. Studies in murine lympho-hematopoiesis have identified a common lymphoid progenitor, which gives rise to all lymphoid cells (T and B cells), and a common myeloid progenitor, which gives rise to granulocytes, macrophages, megakaryocytes and erythrocytes. 8, 9 A human common lymphoid progenitor and a human common myeloid progenitor have recently also been identified in the adult BM. 10 Indeed, our case showing a different origin of the myeloid and lymphoid compartment is in line with this hierarchical model of hematopoiesis. Letter to the Editor To our knowledge, this is the first report of long-term lymphoid-restricted split chimerism in a leukemia patient treated with myeloablative therapy. In patients with persisting MC, subset-specific analyses of chimerism should be considered.
